Head-To-Head Comparison of Different Solubility-Enabling Formulations of Etoposide and Their Consequent Solubility-Permeability Interplay

Journal of Pharmaceutical Sciences

Volumn 104, Issue 9, 2015, Pages 2941-2947

  Beig, Avital ^a   Miller, Jonathan M ^b   Lindley, David ^b   Carr, Robert A ^b   Zocharski, Philip ^b   Agbaria, Riad ^a   Dahan, Arik ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b ABBVIE INC   (United States)

Author keywords

BCS; intestinal permeability; oral drug absorption; solubility enabling formulations; solubility permeability interplay

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; DODECYL SULFATE SODIUM; ETOPOSIDE; MACROGOL 400; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ARTIFICIAL MEMBRANE; BETA CYCLODEXTRIN DERIVATIVE; CYCLODEXTRIN; MACROGOL DERIVATIVE; SURFACTANT;

APPARENT PERMEABILITY; ARTICLE; ARTIFICIAL MEMBRANE; BINDING AFFINITY; COMPARATIVE STUDY; CRITICAL MICELLE CONCENTRATION; DISPERSION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; THEORETICAL MODEL; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECTS; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SOLUBILITY;

ADMINISTRATION, ORAL; BETA-CYCLODEXTRINS; CELL MEMBRANE PERMEABILITY; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; ETOPOSIDE; INTESTINAL ABSORPTION; MEMBRANES, ARTIFICIAL; POLYETHYLENE GLYCOLS; SODIUM DODECYL SULFATE; SOLUBILITY; SURFACE-ACTIVE AGENTS;

EID: 84939269694     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24496     Document Type: Article

References (35)

1. Dahan A, Wolk O, Kim YH, Ramachandran C, Crippen GM, Takagi T, Bermejo M, Amidon GL,. 2013. Purely in silico BCS classification: Science based quality standards for the world's drugs. Mol Pharm 10 (11): 4378-4390.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ,. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46 (1-3): 3-26.
3. Pham-The H, Garrigues T, Bermejo M, González-Álvarez I, Monteagudo MC, Cabrera-Pérez MÁ,. 2013. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number. Mol Pharm 10 (6): 2445-2461.
4. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S,. 2011. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int J Pharm 420 (1): 1-10.
5. Ku MS,. 2008. Use of the biopharmaceutical classification system in early drug development. AAPS J 10 (1): 208-212.
6. Lennernäs H, Abrahamsson B,. 2005. The use of biopharmaceutic classification of drugs in drug discovery and development: Current status and future extension. J Pharm Pharmacol 57 (3): 273-285.
7. Wolk O, Agbaria R, Dahan A,. 2014. Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development. Drug Design Dev Ther 2014 (8): 1563-1575.
8. Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter CJH,. 2013. Strategies to address low drug solubility in discovery and development. Pharm Rev 65 (1): 315-499.
9. Cherniakov I, Domb A, Hoffman A,. 2015. Self-nano-emulsifying drug delivery systems: An update of the biopharmaceutical aspects. Expert Opin Drug Deliv (in Press).
10. Miller JM, Dahan A, Gupta D, Varghese S, Amidon GL,. 2009. Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs. J Control Release 137 (1): 31-37.
11. Jain P, Yalkowsky SH,. 2007. Solubilization of poorly soluble compounds using 2-pyrrolidone. Int J Pharm 342 (1-2): 1-5.
12. Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodríguez-Hornedo N,. 2013. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm 453 (1): 101-125.
13. Chen H, Khemtong C, Yang X, Chang X, Gao J,. 2011. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 16 (7-8): 354-360.
14. Brewster ME, Loftsson T,. 2007. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Del Revi 59 (7): 645-666.
15. Newman A, Knipp G, Zografi G,. 2012. Assessing the performance of amorphous solid dispersions. J Pharm Sci 101 (4): 1355-1377.
16. Dahan A, Miller J,. 2012. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs. AAPS J 14 (2): 244-251.
17. Dahan A, Miller J, Amidon G,. 2009. Prediction of solubility and permeability class membership: Provisional BCS classification of the world's top oral drugs. AAPS J 11 (4): 740-746.
18. Amidon GL, Lennernäs H, Shah VP, Crison JR,. 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12 (3): 413-420.
19. Dahan A, Lennernäs H, Amidon GL,. 2012. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm 9 (6): 1847-1851.
20. Lobenberg R, Amidon GL,. 2000. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 50 (1): 3-12.
21. Beig A, Miller JM, Dahan A,. 2013. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off. Eur J Pharm Biopharm 85 (3, Part B): 1293-1299.
22. Buckley ST, Frank KJ, Fricker G, Brandl M,. 2013. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations". Eur J Pharm Sci 50 (1): 8-16.
23. Fischer SM, Flaten GE, Hagesæther E, Fricker G, Brandl M,. 2011. In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: The influence of nonionic surfactants. J Pharm Pharmacol 63 (8): 1022-1030.
24. Beig A, Miller JM, Dahan A,. 2012. Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: The effect of PEG-400 on carbamazepine absorption. Eur J Pharm Biopharm 81: 386-391.
25. Dahan A, Beig A, Ioffe-Dahan V, Agbaria R, Miller J,. 2013. The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: Increased apparent solubility and drug flux through the intestinal membrane. AAPS J 15 (2): 347-353.
26. Frank KJ, Rosenblatt KM, Westedt U, Hölig P, Rosenberg J, Mägerlein M, Fricker G, Brandl M,. 2012. Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: True supersaturation vs. apparent solubility enhancement. Int J Pharm 437 (1-2): 288-293.
27. Frank KJ, Westedt U, Rosenblatt KM, Hölig P, Rosenberg J, Mägerlein M, Fricker G, Brandl M,. 2014. What is the mechanism behind increased permeation rate of a poorly soluble drug from aqueous dispersions of an amorphous solid dispersion? J Pharm Sci 103 (6): 1779-1786.
28. Miller JM, Beig A, Carr RA, Spence JK, Dahan A,. 2012. A win-win solution in oral delivery of lipophilic drugs: Supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol Pharm 9 (7): 2009-2016.
29. Zur M, Hanson AS, Dahan A,. 2014. The complexity of intestinal permeability: Assigning the correct BCS classification through careful data interpretation. Eur J Pharm Sci 61 (0): 11-17.
30. Higuchi T, Connors KA,. 1965. Phase-solubility techniques. Adv Anal Chem Instrum 4: 117-212.
31. Higuchi T, Kristiansen H,. 1970. Binding specificity between small organic solutes in aqueous solution: Classification of some solutes into two groups according to binding tendencies. J Pharm Sci 59 (11): 1601-1608.
32. Dahan A, Duvdevani R, Shapiro I, Elmann A, Finkelstein E, Hoffman A,. 2008. The oral absorption of phospholipid prodrugs: In vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J Control Release 126 (1): 1-9.
33. Zur M, Gasparini M, Wolk O, Amidon GL, Dahan A,. 2014. The low/high BCS permeability class boundary: Physicochemical comparison of metoprolol and labetalol. Mol Pharm 11 (5): 1707-1714.
34. Beig A, Agbaria R, Dahan A,. 2013. Oral delivery of lipophilic drugs: The tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations. PLoS One 8 (7): e68237.
35. Miller JM, Dahan A,. 2012. Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: Model validation. Int J Pharm 430 (1-2): 388-391.